Healthcare.
From DTC telehealth disruption to gene editing frontiers — we analyze healthcare equities at the intersection of clinical science, regulatory pathways, and the unit economics that determine which innovations become sustainable businesses and which remain promising science.
Our Thesis
Healthcare is in the middle of several simultaneous disruptions that are creating both enormous opportunities and significant risks for equity investors. The GLP-1 revolution is reshaping not just obesity treatment but the entire cardiovascular, metabolic, and related disease landscape — with implications for every company from food manufacturers to medical device makers to health insurers. Direct-to-consumer telehealth platforms are bypassing traditional healthcare distribution channels, building subscription businesses with software-like margins on pharmaceutical products. And gene therapy is moving from science fiction to approved treatments, with base editing and CRISPR technologies promising to cure genetic diseases with a single administration.
Our approach to healthcare investing differs from traditional biotech analysis. We do not attempt to predict clinical trial outcomes — that is a probability game best left to specialist biotech funds with deep scientific advisory boards. Instead, we focus on identifying companies where the science is already proven (or nearly so) and the investment question is about commercial execution, unit economics, regulatory pathway clarity, and market structure dynamics. A telehealth company with a proven DTC acquisition model, clear LTV/CAC economics, and regulatory tailwinds is a business analysis problem, not a clinical trial bet. Similarly, a gene therapy company with approved products and a visible pipeline is a commercial model analysis, not a Phase 1 speculation.
The healthcare companies in our coverage universe share a common characteristic: they operate at the intersection of genuine clinical innovation and scalable business models. Hims & Hers has built a DTC platform that is disrupting how consumers access dermatology, sexual health, weight management, and mental health treatments. Beam Therapeutics is developing base editing technology that offers precision advantages over traditional CRISPR. KalVista Pharmaceuticals is advancing oral treatments for hereditary angioedema and diabetic macular edema. Each represents a different modality but shares the characteristic of operating in spaces where the clinical need is clear, the competitive landscape is analyzable, and the commercial model can be modeled with reasonable confidence.
Research Framework
DTC Telehealth Unit Economics
- •Customer acquisition cost (CAC) by channel: paid social, search, organic, referral, brand
- •Lifetime value (LTV) modeling: subscription retention curves, ARPU expansion, cross-sell rates
- •LTV/CAC ratio trends by product vertical (dermatology, weight loss, mental health, sexual health)
- •Fulfillment economics: pharmacy operations, compounding margins, branded vs. generic mix
- •Regulatory moat: state licensing, DEA scheduling, telehealth prescribing authority post-COVID
GLP-1 Market Analysis
- •Total addressable market sizing: obesity (BMI 30+), overweight (BMI 25-30), adjacent indications
- •Competitive landscape: Novo Nordisk (semaglutide), Eli Lilly (tirzepatide), Amgen, Viking, Roche pipelines
- •Compounding disruption: 503A/503B pharmacy economics, FDA enforcement risk, quality control
- •Insurance coverage trajectory: employer adoption, Medicare negotiation, state Medicaid expansion
- •Second-order effects: reduced bariatric surgery, lower cardiovascular events, food industry impact
Gene Therapy & Editing
- •Technology platform comparison: base editing vs. prime editing vs. traditional CRISPR vs. TALENs
- •Delivery vector analysis: AAV serotypes, lipid nanoparticles, ex vivo vs. in vivo approaches
- •Clinical pipeline tracking: Phase 1/2/3 milestones, regulatory designations (BTD, RMAT, orphan)
- •Manufacturing scalability: viral vector production capacity, GMP constraints, COGS reduction curves
- •Pricing and reimbursement: value-based agreements, outcomes-based contracts, gene therapy ICER models
FDA Regulatory Pathway Analysis
- •Accelerated approval pathway: surrogate endpoints, confirmatory trial requirements, withdrawal risk
- •REMS (Risk Evaluation & Mitigation Strategies): distribution constraints, monitoring requirements
- •Biosimilar competition timelines: reference product exclusivity, patent dance, interchangeability
- •PDUFA date tracking and AdCom voting pattern analysis for coverage universe names
- •International regulatory harmonization: EMA, PMDA filing strategies and approval timing
How We Analyze a DTC Healthcare Platform
Step 1: Acquisition Channel Economics
Direct-to-consumer healthcare platforms live and die by customer acquisition economics. We decompose CAC by channel — paid social (Meta, TikTok), search (Google, Bing), influencer/affiliate, organic/SEO, and brand awareness — and track blended CAC trends over time. A platform like Hims & Hers that can acquire subscribers at $50-80 CAC with 12-month payback periods has fundamentally different economics than one spending $200+ per subscriber. We also analyze channel diversification risk: a company dependent on a single acquisition channel (e.g., 60%+ from Meta ads) faces concentration risk if that platform changes its algorithm, pricing, or healthcare advertising policies. Sustainable DTC businesses build multi-channel acquisition engines with increasing organic/referral mix over time.
Step 2: Subscription Retention & Expansion
Healthcare subscriptions have inherently different retention dynamics than software subscriptions. A patient on a GLP-1 weight loss program may churn after reaching their goal weight or due to side effects. A dermatology subscriber may churn seasonally. A mental health subscriber may have the highest retention but lowest ARPU. We model cohort-level retention curves by product category, adjusting for seasonality, product satisfaction (measured by NPS and refill rates), and the natural lifecycle of treatment. The most valuable DTC healthcare platforms drive cross-sell — a customer who starts with hair loss treatment and adds skincare and weight management has 3-4x the LTV of a single-product subscriber. We track cross-sell rates, multi-product subscriber percentages, and ARPU expansion within cohorts to assess platform stickiness.
Step 3: Pharmacy & Fulfillment Margin Analysis
The margin profile of a DTC healthcare platform depends critically on its fulfillment model. Companies that operate their own pharmacies (vertically integrated) capture the full spread between product cost and subscription price. Those using compounding pharmacies for customized formulations capture even higher margins on differentiated products. We model the gross margin contribution by product type: generic medications (70-85% gross margin), compounded formulations (75-90%), branded medications (lower margin, higher retention), and OTC/supplement products (50-65%). The mix shift between these categories — particularly the introduction of GLP-1 weight loss products, which command premium pricing — drives margin trajectory. We also assess regulatory risk around compounding: FDA enforcement actions against 503A pharmacies, quality control requirements, and the ongoing debate around compounded GLP-1 products.
Step 4: Competitive Moat Assessment
DTC healthcare is a rapidly growing market attracting significant competition from both startups and incumbents. We evaluate moat depth along several dimensions: brand recognition and trust (critical in healthcare where patients need confidence in their provider), data advantages (treatment outcome data that improves personalization and clinical efficacy over time), regulatory licenses (state-by-state medical licenses, DEA registrations, pharmacy licenses that take years to accumulate), and platform breadth (multi-category platforms have lower marginal CAC per category than single-product competitors). A company with strong brand awareness, millions of active subscribers generating clinical data, and licenses in all 50 states has built a moat that is expensive and time-consuming to replicate — even if no single element is individually impregnable.
Step 5: Valuation & Growth Trajectory
DTC healthcare companies straddle the line between healthcare and consumer subscriptions, and the appropriate valuation framework reflects this hybrid nature. We use a blended approach: SaaS-style metrics (subscriber count, ARPU, net revenue retention, subscriber growth rate) valued at multiples appropriate for their growth and margin profile, overlaid with healthcare-specific risk factors (regulatory changes, compounding restrictions, telehealth prescribing limitations). Revenue growth rates of 25-40% with improving margins and expanding ARPU justify premium multiples, but we discount for regulatory risk using scenario analysis. The FDA's stance on compounded GLP-1 products, state telehealth prescribing laws, and DEA scheduling decisions each represent discrete risk events that we probability-weight into our models. We buy when the market prices in worst-case regulatory outcomes while the base case supports continued growth.
Coverage Universe
- Hims & Hers (HIMS)
- Teladoc Health (TDOC)
- GoodRx (GDRX)
- LifeMD (LFMD)
- Ro (Private)
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Viking Therapeutics (VKTX)
- Amgen (AMGN)
- Structure Therapeutics (GPCR)
- Beam Therapeutics (BEAM)
- CRISPR Therapeutics (CRSP)
- Intellia Therapeutics (NTLA)
- Editas Medicine (EDIT)
- Verve Therapeutics (VERV)
- KalVista Pharmaceuticals (KALV)
- BioMarin (BMRN)
- Ultragenyx (RARE)
- Alexion/AstraZeneca (AZN)
- Sarepta (SRPT)
- Intuitive Surgical (ISRG)
- Dexcom (DXCM)
- Exact Sciences (EXAS)
- Guardant Health (GH)
- Natera (NTRA)
- XBI (Biotech SPDR)
- IBB (iShares Biotech)
- XLV (Health Care Select)
- ARKG (Genomic Rev)
- EDOC (Telehealth)
Current Themes
GLP-1 Compounding Disruption
The availability of compounded semaglutide and tirzepatide through 503A and 503B pharmacies has created a parallel market for GLP-1 weight loss products at 70-90% discounts to branded pricing. DTC platforms like Hims & Hers are building significant revenue streams around compounded GLP-1 offerings. The FDA's ongoing review of compounding eligibility — tied to drug shortage status — creates both opportunity and risk. If branded supply constraints persist, compounding remains available; if supply normalizes, the FDA could restrict compounding, forcing patients to branded products. We model both scenarios and assess the impact on DTC platform revenue, margins, and subscriber retention.
Telehealth Expansion Post-COVID
The pandemic-era telehealth flexibilities that expanded prescribing authority, cross-state licensing, and virtual-first care models are largely becoming permanent through state legislation and federal rule-making. The DEA's extension of telehealth prescribing authority for controlled substances through 2025 and likely beyond removes a key regulatory overhang. DTC healthcare platforms are evolving from single-condition treatment into comprehensive virtual primary care platforms, with each new category (weight loss, mental health, dermatology, sexual health, aging) expanding the addressable market and improving unit economics through cross-sell.
Gene Editing Clinical Inflection
The approval of Casgevy (CRISPR/Vertex's gene therapy for sickle cell disease) marked the beginning of the gene editing therapeutic era. Beam Therapeutics' base editing platform offers potential advantages in precision — editing individual bases without creating double-strand breaks — which could expand the range of treatable genetic diseases while reducing off-target risks. We track the clinical pipeline across base editing, prime editing, and traditional CRISPR approaches, focusing on programs with clear regulatory pathways (orphan drug designation, breakthrough therapy, RMAT) and addressable patient populations that support sustainable commercial models.
Healthcare AI Integration
Artificial intelligence is being integrated across healthcare — from clinical decision support and medical imaging to drug discovery and administrative automation. For our coverage universe, the most immediate impact is on DTC platforms using AI to improve personalization (treatment selection based on patient data), operational efficiency (automated clinical workflows, AI-assisted prescribing), and customer experience (AI health coaches, symptom assessment). Companies that effectively deploy AI to lower costs while improving outcomes will build sustainable competitive advantages. We evaluate AI integration depth, measurable outcome improvements, and the regulatory framework for AI-assisted healthcare delivery.
Interested in our healthcare research?
All inquiries are treated with strict confidentiality.
Investor Inquiries